Formulation and In Vitro Evaluation of Bilayer Tablets of Lansoprazole and Amoxicillin Trihydrate for the Treatment of Peptic Ulcer

Neha Singh1, Durga Pandey1, Nilesh Jain2 and Surendra Jain1

1 Sagar Institute of Research & Technology-Pharmacy, Ayodhya Bypass Road, Bhopal, M.P. India – 462041
2 Sagar Institute of Research Technology & Science-Pharmacy, Near ISRO, Bhopal, M.P. India – 462041

Abstract

The present work involves the formulation development, optimization and In-vitro evaluation of bilayer tablet containing Lansoprazole in the immediate release layer and Amoxicillin in the sustained release layer, using sodium starch glycolate as a super disintegrant for the immediate release layer and the hydrophilic matrix HPMC K100M, hydrophilic matrix Ethyl cellulose are used in the sustained release layer. Bilayer tablet showed as initial burst effect to provide dose of immediate release layer Lansoprazole to control the acid secretion level and the sustained release of Amoxicillin for 24 hours. Immediate and sustained release tablets were formulated by wet granulation method because of the poor flow property of the blends. The prepared bilayer tablet was evaluated for their precompression parameters, physical characterization, in vitro drug content, swelling index, In-vitro floating studies and In-vitro drug release. The release of the lansoprazole from the immediate release layer was found to be 97.46 ± 0.15% in 15 minutes. The release of Amoxicillin from the sustained release floating layer was found to be 98.25 ± 0.14% in 12 hours. Lansoprazole potentiate the effect of Amoxicillin. Hence the bilayer tablets of Lansoprazole and Amoxicillin were used to improve patient compliance towards the effective management of ulcer.

Keywords: bilayer tablet, Lansoprazole, and Amoxicillin, sustained release

INTRODUCTION

Lansoprazole is a proton pump inhibitor (PPI) which inactivates the final step in the gastric acid secretion pathway in gastric parietal cells in a dose-dependent manner. Bioavailability is 85% after the first dose – the highest among PPIs and acid inhibition is swift, resulting in rapid relief of symptoms. Lansoprazole also exhibits antibacterial activity against Helicobacter pylori in vitro. Lansoprazole is also effective in combination with different regimens for H. pylori eradication and is included in the first-line PPI-based options for this purpose.

Amoxicillin is a semi-synthetic aminopenicillin, with a broad-spectrum bactericidal activity, used as trihydrate in oral products. Amoxicillin trihydrate is likely a white or almost white crystalline powder, and it is well absorbed when given orally, with a bioavailability (95 Orally%) that appears to be much higher than expected based on its physicochemical and biopharmaceutical properties, and the pH partition theory. Because of its poor solubility, amoxicillin trihydrate can be considered as a drug-candidate which may give rise to dissolution-related bioavailability problems.

Bi-layer tablet is a unit compressed tablet dosage form intended for oral application. It contains two layers in which one layer having conventional or immediate release part of single or multiple active ingredients, another layer is sustained or controlled release part of single or multiple active ingredients.

Nowadays various developed and developing countries move towards combination therapy for treatment of various diseases and disorders requiring long term therapy such as hypertension, diabetes and cardiovascular diseases. Combination preparation plays an important role in clinical treatment because of its better and wider curative synergism and weaker side effects. Combination therapy may be achieved by giving separate drugs or where available by giving combination drugs (monolithic or bilayer dosage form) which are dosage forms that contain more than one active ingredient.

To provide effective, safe and stable pharmaceutical oral formulation containing anti-ulcer drug Lansoprazole as immediate release layer and oral antibiotic drug Amoxicillin as sustained release layer for effective treatment of peptic ulcer.
drug plasma concentration followed by continuation of drug release from the sustained release layer.

MATERIALS AND METHODS

Lansoprazole and Amoxicillin were received as gift by Sri Pharmacare Powai, Mumbai, India. HPMC K100M, Ethyl cellulose, Sodium starch glycolate, Polyvinyl pyrrolidone K 30, Magnesium stearate, Talc, Microcrystalline cellulose, Isopropyl alcohol, obtained from S.D. fine chemicals, Mumbai. Sodium bicarbonate, citric acid, magnesium stearate and talc were obtained from Loba Chemical Pvt Ltd (Mumbai, India). All other chemical was purchased from Hi Media, Mumbai. Double distilled water was prepared freshly and used whenever required. All other chemicals used in this study including those stated were of analytical reagent (A.R.) grade.

Formulation Development

Formulation of Immediate release granules of Lansoprazole

To improve the onset of action the immediate granules of lansoprazole were prepared by wet granulation technique. Sodium starch glycolate (SSG) was used as a super disintegrant in 4%, 6% and 8% concentrations to improve the dissolution of the drug. The granules were compressed by 10 station compression machines. Composition of tablets is mentioned in Table 1. The immediate release tablet of lansoprazole was formulated and optimized. The optimized formulation was used for the final bilayer tablets.

| S.NO | Ingredients                  | N-1(mg) | N-2(mg) | N-3(mg) |
|------|------------------------------|---------|---------|---------|
| 1    | Lansoprazole                 | 15      | 15      | 15      |
| 2    | Sodium starch glycolate      | 8       | 12      | 16      |
| 3    | Polyvinyl pyrrolidone K-30   | 8       | 8       | 8       |
| 4    | Magnesium stearate           | 4       | 4       | 4       |
| 5    | Talc                         | 2       | 2       | 2       |
| 6    | Microcrystalline cellulose   | 162     | 158     | 154     |
| 7    | Lake ponceau 4R              | 1       | 1       | 1       |
| 8    | Isopropyl alcohol            | q.s     | q.s     | q.s     |
| Total weight |                     | 200     | 200     | 200     |

Formulation of amoxicillin sustained release tablets

The sustained release granules were prepared by wet granulation technique. Different polymers such as HPMC K 100 M and Ethyl cellulose were used in different ratios. The tablets were compressed by 10 station compression machine using mm punches. The optimized batch of sustained release tablets of amoxicillin was then compressed with the optimized batch of immediate release Lansoprazole tablets to get bilayer tablets. Composition of tablets is mentioned in Table 2. The sustained release tablet of amoxicillin was formulated and optimized. The optimized formulation was used for the final bilayer tablets.

| S.NO | Ingredients                  | NA-1(mg) | NA-2(mg) | NA-3(mg) | NA-4(mg) | NA-5(mg) |
|------|------------------------------|----------|----------|----------|----------|----------|
| 1    | Amoxicillin                  | 500      | 500      | 500      | 500      | 500      |
| 2    | HPMC K100 M                  | -        | 50       | 25       | 50       | 75       |
| 3    | Ethyl cellulose              | 50       | -        | 25       | 25       | 25       |
| 4    | Polyvinyl pyrrolidone        | 12.5     | 12.5     | 12.5     | 12.5     | 12.5     |
| 5    | Magnesium stearate           | 10       | 10       | 10       | 10       | 10       |
| 6    | Talc                         | 2.5      | 2.5      | 2.5      | 2.5      | 2.5      |
| 7    | Microcrystalline cellulose   | 165      | 165      | 165      | 140      | 115      |
| 8    | Isopropyl alcohol            | q.s      | q.s      | q.s      | q.s      | q.s      |
| Total weight |                        | 740      | 740      | 740      | 740      | 740      |

Formulation of bilayer tablet

Optimized formulation N-3 of Instant release layer (Lansoprazole) and optimized formulation of NA-5 (Amoxicillin) for control release used for formulation of Bi-layer tablet. Optimized immediate layer of Lansoprazole was prepared by wet granulation method. Optimized sustained release layer of Amoxicillin was prepared by wet granulation method.


**Evaluation of Precompression Parameter**

### Angle of repose (θ)

The angle of repose was determined by using fixed funnel method. The physical mixtures of drug with different excipients were prepared and the accurately weighed drug powder or its physical mixture was taken in a funnel. The height of the funnel was adjusted in such a way that the tip of the funnel just touches the apex of the heap of the drug powder. The powder was allowed to flow through the funnel freely onto surface. The angle of repose was calculated using the following equation.

\[ \theta = \tan^{-1} \left( \frac{h}{r} \right) \]

where, \( h \) and \( r \) are the height and radius of the powder cone respectively.

### Bulk density/tapped density

Both loose bulk density (LBD) and tapped density (TBD) were determined were calculated using the following formulas.

\[ \text{LBD} = \frac{\text{Powder weight}}{\text{volume of the packing}} \]

\[ \text{TBD} = \frac{\text{Powder weight}}{\text{tapped volume of the packing}} \]

### Compressibility index

The compressibility index of the granules was determined by Carr’s compressibility index.

\[ \text{Carr’s index (\%)} = \frac{[\text{TBD} – \text{LBD}]}{\text{TBD}} \times 100. \]

### Hausner’s ratio

Hausner's ratio is an indirect index of ease of measuring the powder flow. It was calculated by the following formula7-9.

\[ \text{Hausner’s ratio} = \frac{\text{Tapped density}}{\text{Bulk density}} \]

### Evaluation of Post Compression Parameter

#### Shape and color of tablets

Uncoated tablets were examined under a lens for the shape of the tablet and colour was observed by keeping the tablets in light.

#### Thickness

Three tablets were picked from each formulation randomly and thickness was measured individually. It is expressed in mm and standard deviation was also calculated. The tablet thickness was measured using dial-caliper (Mitutoyo, Japan).

#### Hardness

For each formulation, the hardness of five tablets was determined using the Monsanto hardness tester and measured in terms of Kg/cm².

#### Weight variation

Twenty tablets were selected randomly from each formulation and average weight was determined. The tablets were weighed individually and compared with average weight. The U.S Pharmacopoeia allows a little variation in formulation and average weight was determined. The tablets were removed from the friabilator, de-dusted and weighed. The percent loss in weight due to abrasion and impact was calculated as,

\[ \% \text{Friability} = \frac{\text{Loss in weight}}{\text{Initial weight}} \times 100 \]

#### Friability

A sample of twenty randomly selected tablets were accurately weighed and placed in a Roche friabilator. The friabilator was operated for 4 min at a speed of 25 rpm. The tablets were removed from the friabilator, de-dusted and weighed. The percent loss in weight due to abrasion and impact was calculated as,

\[ \% \text{Friability} = \frac{\text{Loss in weight}}{\text{Initial weight}} \times 100 \]

### Hardness test

The hardness of tablet was measured by Pfizer hardness tester and results were expressed in Kg/cm².

### Drug Content Study

1. **For IR Tablets Containing Lansoprazole**

Twenty tablets were selected randomly, weighed and finely grounded. An accurately weighed quantity of powder equivalent to 10mg of Lansoprazole was transferred to a 100ml volumetric flask and dissolved. The volume was made up to the mark with 0.1M HCl. From this solution 10ml was taken and further diluted with 0.1M HCl in a 100ml volumetric flask. The absorbance of the resulting solution was measured at 281 nm taking 0.1M HCl as blank using UV-Visible spectrophotometer. The concentration was obtained from the calibration graph.

2. **For SR Tablets Containing Amoxycillin**

Twenty tablets were selected randomly, weighed and finely grounded. An accurately weighed quantity of powder equivalent to 50mg of Amoxycillin was transferred to a 100ml volumetric flask and dissolved in 5ml of 0.1N NaOH and the volume was made up to the mark with pH 6.8 phosphate buffer. From this solution 10ml was taken and further diluted with pH 6.8 phosphate buffer in a 100ml volumetric flask. From this solution 5ml was taken and diluted with pH 6.8 phosphate buffer in 50ml volumetric flask. The absorbance of the resulting solution was measured at 228 nm taking pH 6.8 phosphate buffer as blank using UV-Visible spectrophotometer. The concentration was obtained from the calibration graph.

3. **Bilayer Tablets of Lansoprazole and Amoxycillin (Simultaneous Equation Method)**

Simultaneous estimation of Lansoprazole and Amoxycillin was carried out using UV-Visible spectrophotometry. The following equations were used to determine the contents.

\[ C_X = \frac{A_{2y1} - A_{1y2}}{a_2 y_1 - a_1 y_2} \]

\[ C_Y = \frac{A_{1y1} - A_{2y1}}{a_2 y_1 - a_1 y_2} \]

where, \( a_{1x} \) and \( a_{2x} = \) The absorptivity of drug \( X \) at \( \lambda_1 \) and \( \lambda_2 \) respectively. \( a_{y1} \) and \( a_{y2} = \) The absorptivity of drug \( Y \) at \( \lambda_1 \) and \( \lambda_2 \) respectively.

\( A_1 \) and \( A_2 = \) The absorbance of sample at \( \lambda_1 \) and \( \lambda_2 \) respectively.

\( \frac{(A_1/A_2) \times (a_{1x}/a_{2x})}{(a_{y1}/a_{y2})} \)

The ratios should lie outside the range of 0.1 – 2.0 for the precise determination of \( X \) and \( Y \) drugs. This criteria is satisfied only when the \( \lambda_{max} \) of the two components is reasonably dissimilar and the components should not interact chemically.

1. **Preparation of standard stock solution of Lansoprazole**

Lansoprazole equivalent to 100mg was accurately weighed and dissolved. The volume was made up to the mark with pH 6.8 phosphate buffer in 100ml standard phosphate buffer. From this solution 10ml was taken and diluted with pH 6.8 phosphate buffer in 100ml volumetric flask. From this solution 10ml was taken and diluted with pH 6.8 phosphate buffer in 100ml volumetric flask. From this solution 50ml was taken and diluted with pH 6.8 phosphate buffer in 50ml volumetric flask.
was taken and further diluted with pH 6.8 phosphate buffer in 100ml standard flask.

2. Preparation of standard stock solution of Amoxycillin

Amoxycillin equivalent to 100mg was accurately weighed and dissolved. The volume was made up to mark with pH 6.8 phosphate buffer in 100ml standard flask. From this solution 10ml was taken and diluted with pH 6.8 phosphate buffer in 100ml volumetric flask. From this solution 10ml was taken and further diluted with pH 6.8 phosphate buffer in 100ml standard flask.

3. Preparation of sample solution

Twenty tablets were selected randomly, weighed and finely grounded. An accurately weighed quantity of powder equivalent to 100mg of Amoxycillin was transferred to a 100ml volumetric flask and dissolved in 5ml of 0.1N NaOH and the volume was made up to mark with pH 6.8 phosphate buffer. From this solution 10ml was taken and further diluted with pH 6.8 phosphate buffer in a 100ml volumetric flask. From this solution 10ml was taken and further diluted with pH 6.8 phosphate buffer in a 100ml volumetric flask. The absorbance of resulting solution was measured at 281 nm and 228 nm respectively. The amounts of both the drugs were determined.

In Vitro Disintegration Studies for IR Tablets

The disintegration time was determined using disintegration test apparatus. The tablets were placed in each of the six tubes of the basket. The assembly was suspended in 0.1M HCl maintained at a temperature of 37 ± 2°C and the apparatus was switched on. The time taken to disintegrate the tablets completely was noted.

In Vitro Dissolution Studies

1. For IR tablets

The release of Lansoprazole was determined using Type II (paddle) dissolution apparatus under sink condition. 900ml of 0.1M HCl was used as dissolution medium at a temperature of 37.0 ± 0.5°C. The paddle was stirred at a speed of 50 rpm. The release studies were carried out for 30mins. The absorbance of the solution was measured at 281 nm taking 0.1M HCl as blank using UV-Visible spectrophotometer.

2. For SR tablets

The release of Amoxycillin was determined using Type II (paddle) dissolution apparatus under sink condition. 900ml of pH 6.8 phosphate buffer was used as dissolution medium at a temperature of 37 ± 0.5°C. The paddle was stirred at a speed of 50 rpm. The release studies were carried out for 24hours. The absorbance of the solution was measured at 228 nm taking pH 6.8 phosphate buffer as blank using UV-Visible spectrophotometer.

3. For bilayer tablets

The release of bilayer tablet was determined using Type II (paddle) dissolution apparatus under sink condition. 900ml of 0.1M HCl was used as dissolution medium for first two hours followed by pH 6.8 phosphate buffer solution for next eight hours maintained at a temperature of 37 ± 0.5°C. The paddle was stirred at a speed of 50 rpm. The release studies were carried out for ten hours. The absorbance of the solution was measured at 281 nm and 228 nm taking respective buffer solutions as blank using UV-Visible spectrophotometer and the calculations were done by simultaneous equation method.

RESULTS AND DISCUSSION

The present work was aimed to formulate bilayer tablets of immediate release Lansoprazole and sustained release Amoxycillin. The therapy with these drugs offers a good quality of life for patients who are suffering from gastric ulcer.

Preformulation Studies Drug Characterization

Lansoprazole and amoxycillin were tested Description, Loss on drying, Solubility, Melting point as per in house specification and found satisfactory for formulation. The drug source is identified and found complying with the specifications.

Physical compatibility study

The compatibility studies were carried out to study the possible interactions between active ingredients (Lansoprazole & Amoxycillin) and inactive ingredients. Physical mixtures of both API and excipients were prepared separately as per the ratios mentioned in table below and kept for stability at 40°C and 75% RH for one month. Samples were taken out after every 10 days and were subjected to physical and chemical compatibility tests. The physical compatibility study was performed visually. The study implies that the drug and the excipients were physically compatible with each other as there was no change of physical parameters. The excipients which are compatible with the drug were selected for the formulation.

Chemical compatibility study

All the samples were scanned at the wave number region of 4000-400 cm⁻¹ using KBr disc method. This KBr discs were formed by taking drug and KBr in a ratio of 1: 100 respectively. Then this mixture was mixed well in mortar for three to five minutes. A very small amount of this mixture was uniformly spread and sandwiched between the pellets and pressed using KBr pellet press at a pressure of 20,000 psi for 1min. The pressure was then released and pellet was placed into the pellet holder and thus scanned in the IR region. No shift and no disappearance of characteristic peaks suggesting that there is no interaction between the drugs and also with the excipients in the final formulation.

Drug Content study

Calibration Curve of Lansoprazole

Calibration curve of Lansoprazole in 0.1M HCl is shown that the solution of Lansoprazole in 0.1M HCl show linearity (R² = 0.999) at concentrations of 5-25 (µg/ml) and obey Beer Lambert Law at λmax 281 nm.

Calibration Curve for Amoxycillin

Calibration curves of Amoxycillin in pH 6.8 phosphate buffer is shown. It was found that the solution of Amoxycillin in pH 6.8 phosphate buffer show linearity (R² = 0.999) at concentrations of 2-10 (µg/ml) and obey Beer and Lambert Law at λmax 228 nm.

Precompression Study for IR Formulation

The API and the formulated blends were evaluated for precompression parameters and results were shown in table 3.
The bulk density of the IR blends ranged from 0.217 ± 0.36 – 0.224 ± 0.03 g/cm³ and the tapped density ranged from 0.379 ± 0.02 – 0.387 ± 0.01 g/cm³. The compressibility index of the IR blends ranged from 17.69 ± 0.37 – 25.68 ± 0.84% and Hausner’s ratio ranged from 1.26 ± 0.46 – 1.29 ± 0.92. The angle of repose of the IR blends ranged from 30° 37' ± 0.54 – 32° 33' ± 0.91. The formulated blends showed good flow property, so wet granulation technique was used for preparing IR granules of Lansoprazole.

The IR granules were evaluated for bulk density, tapped density, compressibility index, Hausner’s ratio and Angle of repose. The results are given in Table 4.

### Table 4 Precompression Study of Formulated IR Granules

| Formulation | Bulk density g/cm³ | Tapped density g/cm³ | Compressibility index (%) | Hausner’s Ratio | Angle of Repose (Degree) |
|-------------|-------------------|----------------------|---------------------------|-----------------|--------------------------|
| N-1         | 0.213 ± 0.26      | 0.37 ± 0.09          | 23.27 ± 0.88              | 1.26 ± 0.67     | 32° 61' ± 0.39           |
| N-2         | 0.213 ± 0.32      | 0.38 ± 0.43          | 24.83 ± 0.78              | 1.32 ± 0.42     | 31° 40 ± 1.10            |
| N-3         | 0.221 ± 0.42      | 0.35 ± 0.09          | 25.68 ± 0.84              | 1.28 ± 0.63     | 31° 64 ± 0.13            |

Mean ± S.D (n=3)

The bulk density of the IR granules ranged from 0.213 ± 0.26 – 0.224 ± 0.42 g/cm³ and the tapped density ranged from 0.35 ± 0.09 – 0.38 ± 0.43 g/cm³. The compressibility index of the IR granules ranged from 23.27 ± 0.88% – 25.68 ± 0.84% and Hausner’s ratio ranged from 1.26 ± 0.67 – 1.32 ± 0.42. The angle of repose of the IR granules ranged from 31° 40 ± 1.10 – 32° 61' ± 0.39. The formulated IR granules showed good flow property.

### Preparation of IR tablets of Lansoprazole

Wet granulation technique was employed for the formulation of IR granules of Lansoprazole. Three formulations of immediate release layer of Lansoprazole (N1, N2 and N3) were prepared using sodium starch glycolate (super disintegrant) in three different ratios. The granules were compressed using 10 station tablet compression machine using 10/32 punches. The result of Post Compression Study for Tablets was shown in Table 5.

### Table 5 Post Compression Study of the Formulated Tablets

| Formulation | Uniformity of weight (mg) | Diameter (mm) | Thickness (mm) | Hardness (kg/cm²) | % Friability | (% w/w) Drug Content | Disintegration time (sec) |
|-------------|--------------------------|---------------|----------------|-------------------|-------------|----------------------|--------------------------|
| Specified limit | 189.8 – 206.4 | 4.5 – 5.0 | 2.5 – 3 | 3.5 – 4 | Not more than 1.0% | 90 – 110% | |
| N-1         | 197.21 ± 0.35          | 4.9 ± 0.18    | 2.6 ± 0.49    | 3.88 ± 0.48       | 0.67 ± 0.12 | 96.17 ± 0.99      | 42.02 ± 0.79             |
| N-2         | 196.14 ± 0.78          | 4.87 ± 0.09   | 2.62 ± 0.19   | 3.78 ± 0.94       | 0.72 ± 0.02 | 98.44 ± 0.94      | 29.05 ± 0.90             |
| N-3         | 199.38 ± 0.91          | 4.82 ± 0.24   | 2.68 ± 0.03   | 3.72 ± 0.36       | 0.70 ± 0.12 | 99.09 ± 0.32      | 24.07 ± 0.92             |

Mean ± S.D (n=5)

The tablets comply with the test for uniformity of weight, uniform in thickness and diameter have sufficient mechanical strength to resist the transportation. The percentage friability of all the formulations was within the acceptable limits. i.e not more than 1%. The drug contents of all three IR formulations were found to be within the limit. i.e the drug content was not less than 90% and not more than 110% (as per IP: 2010). The disintegration time of the IR tablets ranged from 43.02 seconds to 19.07 seconds. The disintegration time of the IR tablets containing 8% sodium starch glycolate was found to have optimum disintegration time (19.07 seconds) for IR tablets.
In Vitro Dissolution Study

The in vitro dissolution of immediate release formulations of Lansoprazole is shown in table 6 and Fig 1.

Table 6 In Vitro Dissolution Study of Immediate Release Tablets

| Time(minutes) | N-1        | N-2        | N-3        |
|---------------|------------|------------|------------|
| 0             | 0 ± 0.00   | 0 ± 0.00   | 0 ± 0.00   |
| 10            | 62.6 ± 0.61| 80.42 ± 0.16| 87.58 ± 0.31 |
| 20            | 72.43 ± 0.59| 87.43 ± 0.61| 92.49 ± 0.18 |
| 30            | 80.26 ± 0.18| 94.63 ± 0.41| 99.74 ± 0.25 |
| 40            | 85.14 ± 0.42| 97.87 ± 0.41|             |
| 50            | 92.54 ± 0.74|            |             |
| 60            | 97.66 ± 0.70|            |             |

Mean ± S.D (n=3)

The in vitro dissolution study of IR tablets showed that 8% concentration of SSG was found to be optimum for immediate release of Lansoprazole. The 4% and 6% concentration of SSG was found to be releasing the drug slowly when compared to 8% SSG. The 8% concentration of SSG released 98.94% at the end of 30 minutes. Therefore, formulation N-3 was optimized and selected for final bilayer tablets.

Precompression Study for SR Tablets

The API and the formulated blends of SR were evaluated for precompression parameters. The results are given in table 7.

Table 7 Precompression Study of API and Formulated Blends

| API and formulation | Bulk density g/cm³ | Tapped Density g/cm³ | Compressibility Index (%) | Hausner’s ratio | Angle of Repose (Degree) |
|---------------------|--------------------|----------------------|---------------------------|------------------|--------------------------|
| Amoxycillin         | 0.26 ±0.03         | 0.32 ±0.22           | 26.36 ±1.35               | 1.40 ±0.58       | 29° 66’ ±0.03            |
| NA-1                | 0.25 ±0.02         | 0.33 ±0.82           | 25.05 ±1.33               | 1.44 ±0.80       | 30° 34’ ±0.90            |
| NA -2               | 0.27 ±0.02         | 0.29 ±0.42           | 17.02 ±0.69               | 1.69 ±0.85       | 31° 40 ±1.10             |
| NA -3               | 0.27 ±0.03         | 0.31 ±0.60           | 17.82 ±0.01               | 1.81 ±0.97       | 31° 58 ±1.64             |
| NA -4               | 0.27 ±0.06         | 0.33 ±0.12           | 18.70 ±0.14               | 1.17 ±0.08       | 32° 40 ±0.66             |
| NA -5               | 0.26±0.03          | 0.29 ±0.16           | 18.82 ±0.99               | 1.17±0.59        | 31° 83 ±0.64             |

Mean ± S.D (n=3)
The bulk density of the SR blends ranged from 0.25 ±0.02 – 0.27 ±0.06 g/cm³ and the tapped density ranged from 0.29 ±0.16–0.33 ±0.82 g/cm³. The compressibility index ranged from 17.02 ±0.69% and Hausner’s ratio ranged from 1.17 ±0.85–1.69 ±0.85. The angle of repose of the SR blend ranged from 29° 66’ ±0.03–32° 40’ ±0.66. The formulated blends showed good flow property so wet granulation technique was used for preparing SR granules of Amoxycillin. The SR granules were evaluated for bulk density, tapped density, compressibility index, Hausner’s ratio and angle of repose. The results are given in Table 8.

### Table 8 Precompression Study of Sustained Release Granules

| Formulation | Bulk density g/cm³ | Tapped density g/cm³ | Compressibility Index (%) | Hausner’s ratio | Angle of Repose |
|-------------|---------------------|----------------------|---------------------------|----------------|-----------------|
| NA-1        | 0.27 ±0.06          | 0.35 ±0.09           | 22.27 ±1.88               | 1.28 ±0.67     | 3T 24 ±0.90     |
| NA-2        | 0.31 ±0.01          | 0.38 ±0.43           | 18.79 ±0.96               | 1.23 ±0.45     | 3T 21 ±0.39     |
| NA-3        | 0.25 ±0.05          | 0.29 ±0.42           | 15.02 ±0.61               | 1.17 ±0.85     | 3T 78’ ±0.53    |
| NA-4        | 0.26 ±0.13          | 0.31 ±0.60           | 15.82 ±0.69               | 1.18 ±0.07     | 3T 27 ±0.36     |
| NA-5        | 0.27 ±0.26          | 0.33 ±0.82           | 16.70 ±0.14               | 1.20 ±0.08     | 3T 23’ ±0.86    |

Mean ± S.D (n=3)

The bulk density of the SR granules ranged from 0.25 ±0.05–0.31 ±0.01 g/cm³ and the tapped density ranged from 0.29 ±0.42–0.38 ±0.43 g/cm³. The compressibility index ranged from 15.02 ±0.61–22.27 ±1.88% and Hausner’s ratio ranged from 1.17 ±0.85–1.29 ±0.67. The angle of repose of the SR granules ranged from 3T 21’ ±0.39–3T 78’ ±0.53. The formulated SR granules showed good flow property.

### Formulation Development of SR Tablet

Wet granulation technique was employed for the formulation of SR granules of Amoxycillin. Five batches of SR granules were prepared by using hydrophilic polymer HPMC K100M and hydrophobic polymer EC in varying proportions. The formulations were compressed on a 10 station tablet compression machine and the result of post compression study shown in Table 9.

### Table 9 Post Compression Study

| Formulation | Uniformity of weight (mg) | Thickness (mm) | Diameter (mm) | Hardness (Kg/cm²) | Friability Not more than 1.0% | Drug content (%w/w) |
|-------------|--------------------------|---------------|--------------|-------------------|-------------------------------|--------------------|
| Specified limit | 703-777                   | 2.5 - 3.5     | 4.5 - 5.5    | 4-6               |                               | 90-110%            |
| NA-1        | 751.32 ±0.79             | 2.92 ±0.87    | 4.8 ±0.49    | 4.72 ±0.69        | 0.79 ±0.26                    | 96.22 ±0.88        |
| NA-2        | 761.38 ±0.53             | 2.85 ±0.39    | 4.72 ±0.69   | 5.06 ±0.56        | 0.82 ±0.00                    | 98.47 ±0.65        |
| NA-3        | 754.38 ±0.15             | 2.86 ±0.48    | 4.76 ±0.19   | 5.12 ±0.15        | 0.70 ±0.46                    | 97.52 ±0.95        |
| NA-4        | 754.00 ±0.93             | 3.18 ±0.20    | 4.74 ±0.16   | 5.24 ±0.89        | 0.91 ±0.27                    | 98.95 ±0.24        |
| NA-5        | 754.4 ±0.92              | 3.12 ±0.66    | 4.72 ±0.95   | 5.18 ±0.94        | 0.65 ±0.98                    | 99.30 ±0.23        |

Mean ± S.D (n=5)

The tablet complies with the test for uniformity of weight, uniform in thickness, diameter and hardness. The percentage friability of all formulations was within the acceptable limits, i.e. not less than 1%. The drug contents of all five SR formulations were found to be within the limit, i.e. the drug content was not less than 90% and not more than 110% (as per IP: 2010).

### In Vitro Dissolution Study of SR Tablets

The in vitro dissolution study of SR tablets is given in Table 10 and Fig 2.
Table 10: In Vitro Dissolution Study of SR Tablets

| Time (minutes) | NA-1       | NA-2       | NA-3       | NA-4       | NA-5       |
|----------------|------------|------------|------------|------------|------------|
| 0              | 0 ± 0.00   | 0 ± 0.00   | 0 ± 0.00   | 0 ± 0.00   | 0 ± 0.00   |
| 30             | 42.38 ± 0.56 | 41.47 ± 0.55 | 36.34 ± 0.94 | 26.42 ± 0.70 | 23.97 ± 0.42 |
| 60             | 50.55 ± 0.48 | 46.57 ± 0.58 | 41.50 ± 0.11 | 32.59 ± 0.72 | 27.37 ± 0.69 |
| 120            | 58.22 ± 0.32 | 55.56 ± 0.15 | 46.28 ± 0.83 | 39.44 ± 0.68 | 33.59 ± 0.53 |
| 180            | 67.05 ± 0.13 | 65.53 ± 0.33 | 52.28 ± 0.18 | 45.36 ± 0.40 | 39.45 ± 0.72 |
| 240            | 72.56 ± 0.87 | 71.50 ± 0.97 | 59.38 ± 0.59 | 50.45 ± 0.32 | 47.84 ± 0.50 |
| 300            | 81.24 ± 0.75 | 79.31 ± 0.24 | 68.37 ± 0.51 | 56.28 ± 0.84 | 54.10 ± 1.40 |
| 360            | 92.25 ± 0.21 | 84.58 ± 0.30 | 77.45 ± 0.53 | 62.45 ± 0.72 | 59.57 ± 0.60 |
| 420            | 96.39 ± 0.91 | 90.64 ± 0.51 | 83.28 ± 0.87 | 67.25 ± 0.54 | 67.53 ± 1.14 |
| 480            | 98.42 ± 0.90 | 97.49 ± 0.82 | 88.78 ± 0.22 | 73.28 ± 0.93 | 68.40 ± 0.56 |
| 540            | 99.51 ± 0.46 | 93.35 ± 0.94 | 79.26 ± 0.34 | 77.54 ± 0.34 | 84.78 ± 0.59 |
| 600            | 99.23 ± 0.25 | 87.92 ± 0.23 | 72.48 ± 0.15 | 70.45 ± 0.72 | 67.85 ± 0.46 |
| 660            | 99.73 ± 0.83 | 92.34 ± 0.85 | 89.82 ± 0.95 | 77.54 ± 0.34 | 84.78 ± 0.59 |
| 720            | 99.23 ± 0.25 | 87.92 ± 0.23 | 72.48 ± 0.15 | 70.45 ± 0.72 | 67.85 ± 0.46 |

Mean ± S.D (n=3)

Figure 2: In vitro dissolution study of SR tablets

Based on the comparative release profile, formulation NA-5 was selected for the final bilayer tablets.

Formulation Development: Preparation of Bilayer Tablets

Optimized immediate layer of Lansoprazole was prepared by wet granulation method. Optimized sustained release layer of Amoxycillin was prepared by wet granulation method. The granules were compressed on 10 station bilayer tablet compression machines and result were shown in table 11.

Table 11: Post Compression Study of Bilayer Tablets

| Parameters                          | Bilayer tablet |
|-------------------------------------|----------------|
| Uniformity of weight (mg)           | 824.18 ± 0.63  |
| Thickness (mm)                      | 5.21 ± 0.07    |
| Diameter (mm)                       | 4.71 ± 0.15    |
| Hardness (kg/cm²)                   | 5.02 ± 0.28    |
| Friability (%)                      | 0.37 ± 0.13    |
| Drug content* (simultaneous estimation method) |
| 1. Lansoprazole                     | 1.97 ± 0.15    |
| 2. Amoxycillin                      | 2.98 ± 0.14    |

Mean ± S.D (n=5)

*Mean ± S.D (n=3)

Figure 3: The in vitro dissolution study of Lansoprazole in bilayer tablet

In Vitro Dissolution Study of Lansoprazole in Bilayer Tablet

The in vitro dissolution study of drugs in bilayer tablets is given in table 6.12 and Fig 3.

Table 12: The in vitro dissolution study of Lansoprazole in bilayer tablet

| Time (minutes) | % Drug release |
|----------------|---------------|
| 0              | 0 ± 0.00      |
| 10             | 78.27 ± 0.26  |
| 20             | 92.24 ± 0.12  |
| 30             | 97.46 ± 0.15  |

Mean ± S.D (n=3)
**Table 13: In Vitro Dissolution Study Of Amoxycillin In Bilayer Tablet**

| Time (minutes) | % Drug release |
|----------------|----------------|
| 0              | 0 ± 0.00       |
| 30             | 18.32 ± 0.15   |
| 60             | 27.14 ± 0.91   |
| 120            | 33.21 ± 0.14   |
| 180            | 38.24 ± 0.25   |
| 240            | 46.27 ± 0.15   |
| 300            | 55.66 ± 0.48   |
| 360            | 60.15 ± 0.69   |
| 420            | 67.71 ± 0.07   |
| 480            | 72.16 ± 0.43   |
| 540            | 79.47 ± 0.31   |
| 600            | 85.15 ± 0.65   |
| 660            | 91.17 ± 0.41   |
| 720            | 98.25 ± 0.14   |

Mean ± S.D (n=3)

**Figure 4 In vitro dissolution study of Amoxycillin in bilayer tablet**

**CONCLUSION**

Lansoprazole and amoxycillin bilayer tablet have a promising potential as an alternative to the conventional dosage form. This new dosage form has commercial marketing potency as no such delivery systems are presently available in market.

**REFERENCES**

1. Matheson AJ, Jarvis B. Lansoprazole. Drugs. 2001; 61(12):1801-33.
2. Bown RL. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. International journal of clinical practice. 2002; 56(2):132-9.
3. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter. 1998; 3(1):21-7.
4. Korolkovas, A. Essentials of Medicinal Chemistry, 2nd ed., New York: Wiley-Interscience. 1988: 1216.
5. Devani MB, Patel IT, Patel TM. Spectrophotometric determination of amoxycillin and its dosage forms. Journal of pharmaceutical and biomedical analysis. 1992; 10(5):355-8.
6. Bird AE. Amoxicillin. InANalytical profiles of drug substances and excipients 1994; 23: 1-52.
7. Carceles CM, Escudero E, Vicente MS, Serrano JM, Carli S. Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and oral administration in goats. Veterinary Quarterly. 1995; 17(4):134-8.
8. Pasqualoto KF, Funck JA, Silva FE, Kratz C. Development and Evaluation of Amoxicillin Formulations by Direct Compression: Influence of the Adjuvants on Physicochemical and Biopharmaceutical Properties of the Tablets. Acta Pharmaceutica Bonaerense. 2005; 24(1):39-47.
9. Westphal JF, Deslandes A, Brogard JM, Carbon C. Reappraisal of amoxicillin absorption kinetics. Journal of antimicrobial chemotherapy. 1991; 27(5):647-54.
10. Kumar AH, Kavitha K, Kumar SA, Kumar MR, Singh SD. Novel Approach of bilayer tablet technology—a review. International journal of pharmaceutical, Chemical & Biological Sciences. 2013; 3(3):887-893.
11. Lopes CM, Lobo JM, Pinto JF, Costa PC. Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen. Aaps PharmSciTech. 2007; 8(3):195-202.
12. Maggi L, Machiste EO, Torre ML, Conte U. Formulation of biphasic release tablets containing slightly soluble drugs. European journal of pharmaceutics and biopharmaceutics. 1999; 48(1):37-42.
13. Lieberman HA, Lachman L, Schwarz JB. Pharmaceutical dosage forms: Tablets. New York and Basel.: Marcel Dekker, 1989; 2:1-54.
14. Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry, part-II. CBS Publications and Distributors, New Delhi 1997; 1275-320.
15. Vinod KR, Suri AP, Banji D, Anbazhagan S, Vasa S, Sandhya S. Formulation and in vitro characterization of lansoprazole floating gastroretentive microspheres by modified non aqueous solvent evaporation method. Der Pharma Chemica. 2010; 2(5):500-6.